Optimal treatment strategy with nilotinib for patients with newly diagnosed chronic‐phase chronic myeloid leukemia based on early achievement of deep molecular response (MR 4.5 ): The phase 2, multicenter N‐Road study-Reference-Cited by-同舟云学术

Optimal treatment strategy with nilotinib for patients with newly diagnosed chronic‐phase chronic myeloid leukemia based on early achievement of deep molecular response (MR 4.5 ): The phase 2, multicenter N‐Road study

Published:2020-04-06 Issue:11 Volume:9 Page:3742-3751
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Nishiwaki Kaichi¹^ORCID,Sugimoto Kei‐ji²,Tamaki Shigehisa³,Hisatake Junichi⁴,Yokoyama Hisayuki⁵,Igarashi Tadahiko⁶,Shinagawa Atsushi⁷,Sugawara Takeaki⁸,Hara Satoru⁹,Fujikawa Kazuhisa¹⁰,Shimizu Seiichi¹¹,Yujiri Toshiaki¹²,Tojo Arinobu¹³,Wakita Hisashi¹⁴

Affiliation:

1. Division of Oncology and Hematology Jikei University Kashiwa Hospital Kashiwa Japan

2. Division of Hematology Juntendo University Urayasu Hospital Chiba Japan

3. Department of Hematology/Infectious Disease Ise Red Cross Hospital Ise Japan

4. Department of Hematology Omori Red Cross Hospital Tokyo Japan

5. Department of Hematology National Hospital Organization Sendai Medical Center Sendai Japan

6. Division of Hematology and Oncology Gunma Cancer Center Ohta Japan

7. Department of Internal Medicine Hitachi General Hospital Ibaraki Japan

8. Division of Hematology‐Oncology Chiba Cancer Center Chiba Japan

9. Department of Hematology Chiba Rosai Hospital Chiba Japan

10. Department of Hematology Chibaken Saiseikai Narashino Hospital Narashino Japan

11. Department of Hematology Tsuchiura Kyodo General Hospital Tsuchiura Japan

12. Third Department of Internal Medicine Yamaguchi University Yamaguchi Japan

13. Division of Molecular Therapy Institute of Medical Science Tokyo University Tokyo Japan

14. Division of Hematology and Oncology Japanese Red Cross Society Narita Red Cross Hospital Narita Japan

Funder

Novartis Pharma KK

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.3034

Reference30 articles.

1. Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia

2. Chronic myelogenous leukemia: A review and update of therapeutic strategies

3. Cancer Statistics, 2004

4. Clinical and epidemiologic burden of chronic myelogenous leukemia

5. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 18 months follow-up of deep molecular response 4.5 (MR4.5) with nilotinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a prospective, multi-center study in China;Frontiers in Medicine;2023-11-16

2. Early dynamics of chronic myeloid leukemia on nilotinib predicts deep molecular response;npj Systems Biology and Applications;2022-10-13

3. Early Dynamics of Chronic Myeloid Leukemia on Nilotinib Predicts Deep Molecular Response;2021-02-17